<DOC>
	<DOCNO>NCT00083382</DOCNO>
	<brief_summary>The purpose research study helpful combination thalidomide Pamidronate thalidomide Zometa control myeloma disease study side effect .</brief_summary>
	<brief_title>Combination Bisphosphonate Anti-Angiogenesis Therapy With Pamidronate Thalidomide</brief_title>
	<detailed_description>Recently laboratory research find thalidomide inhibit formation new blood vessel necessary growth spread cancer . In order grow increase size tumor require new blood vessel supply necessary blood grow . If prevent new blood vessel feed tumor form use thalidomide might slow stop growth tumor . This concept call `` anti-angiogenesis '' It hop thalidomide slow stop growth myeloma . However , guaranteed benefit take part study . The treatment receive may even harmful .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Patients must diagnosis Smoldering Indolent myeloma All patient must inform investigational nature study must sign write informed consent accordance UAMS Human Research Advisory Committee federal guideline . Prior bisphosphonate therapy within 30 day prior study entry . Serum creatinine &gt; 5 mg/dl , ascites , serum direct bilirubin &gt; 2.5 mg/dl . Prior plicamycin calcitonin within 2 week study entry . Severe cardiac disease , unstable thyroid disease , epilepsy . Prior radiation therapy &gt; 20 % skeleton .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Myeloma</keyword>
	<keyword>Thalidomide</keyword>
	<keyword>Pamidronate</keyword>
	<keyword>Aredia</keyword>
	<keyword>Bisphosphonate</keyword>
	<keyword>Anti-Angiogenesis</keyword>
	<keyword>Smoldering/Indolent Myeloma</keyword>
	<keyword>Zometa</keyword>
</DOC>